Company aims to harness the therapeutic potentia

Regenxbio Inc.

Moves by a chipmaker and a pharma giant signal h

The peptide therapeutics market is projected to g

MBX Biosciences, Inc.

Dyno Therapeutics, a genetic technologies company

LifeVantage Corporation held its 2026 Global Kick

Saudi Arabia adds 13 new researchers to its grow

Juvena Therapeutics, a clinical‑stage biotechno

The global geriatric care devices market is expec

Pauling.

Co-founder Hanadie Yousef to step down as CEO as

FDA designation fast-tracks a promising therapy

BioAge’s oral drug sharply reduced heart-linke

Ahead Health lands $6m in seed funding to accele

Mesoblast Limited reported that sales of its allo

Alnylam Pharmaceuticals has launched its Alnylam

Omada Health, a digital health provider focused o

Function Health announced the launch of a new int

From elite motorsport to aging science, Formula

Japanese research team demonstrates a living ski

Agency says non-medical health data won’t be r

Phase 1b trial of dual agonist results reveal st

Gordian Bio and Pfizer Inc.

A peer‑reviewed study has demonstrated consiste

Aspen Neuroscience, a clinical‑stage biotechnol

Israel-based medtech targets easier, better-tole

Looking toward London 2026, new speakers broaden

NRG Therapeutics takes a first-in-human step tow

Phase 1b results for GT-02287 point to biologica

Studies of Brazilians living past 110 suggest re

Function launches new initiative that challenges

AstronauTx Ltd.

Amylyx Pharmaceuticals, Inc.

Omada Health said a 12‑month real‑world analy

The global GLP-1 market is forecast to expand sig

Anavex Life Sciences Corp.

Function announced the launch of a new app within

NRG Therapeutics Ltd.

Introduction of ChatGPT Health comes amid widesp

TECregen lands seed funding for mission to comba

Companies seek new obesity targets using platfor

The global gene therapy research and development

Aperture Therapeutics announced the launch of a f

Novoron Bioscience said it has received a $2.

Cymbiotika, a San Diego-based science-backed well

FibroBiologics, Inc.

First-in-class neurodegeneration drug nears Phas

FDA designation accelerates development of a nov

Relation Therapeutics Limited said it has entered